Drugs / FT522
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05950334 | Nov 2023 → Jun 2025 | B-cell non-Hodgkin lymphoma | Fate Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-11-18 | Fate Therapeutics | Results Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence fatetherapeutics.com ↗
Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, and Persistence of FT522 Live Cells |
| 2024-11-12 | Fate Therapeutics | Regulatory Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates fatetherapeutics.com ↗
FT522 Multi-indication IND Application for Conditioning-free Treatment of B Cell-mediated Autoimmune Diseases Allowed by FDA |
| 2024-05-09 | Fate Therapeutics | Results Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program fatetherapeutics.com ↗
In initial clinical observations from the Company’s ongoing Phase 1 BCL study, the first two patients treated with FT522 showed rapid, deep, and sustained B-cell depletion in the periphery throughout the one-month treatment cycle. |
| 2024-05-03 | Fate Therapeutics | Results Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting fatetherapeutics.com ↗
These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-18 | Fate Therapeutics | Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence fatetherapeutics.com ↗ |
| 2024-11-12 | Fate Therapeutics | Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates fatetherapeutics.com ↗ |
| 2024-05-09 | Fate Therapeutics | Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program fatetherapeutics.com ↗ |
| 2024-05-03 | Fate Therapeutics | Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting fatetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950334 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT05950334 ↗ |